| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Aug 3, 2021Approval received to co-package a convenience administration kit along with the product BERINERT.
KING OF PRUSSIA, PA 03 Aug 2021 CSL Behring, a global biotherapeutics leader received U.S. Food and Drug Administration (FDA) approval for its supplemental request (submitted Aug. 30, 2020) for...
-
Jun 8, 2021Hizentra will be covered under the same Medicare benefit category as intravenous immune globulin (IVIg), but with the convenience of self-infusing at home
KING OF PRUSSIA, Pa. 08 Jun 2021 Global biotherapeutics leader CSL Behring today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Hizentra for coverage under Medicare...
-
Jun 2, 2021CSL continues to provide medicines to patients around the world.
Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues to provide medicines to patients around the world. We’re also exploring new...
-
May 16, 2021Findings signal need for novel treatment strategies to provide more protection during this high-risk, 90-day period
KING OF PRUSSIA, Pa. 16 May 2021 Global biotherapeutics leader CSL Behring today announced the results of a new meta-analysis of seven interventional Phase 3 clinical trials that included more...
-
May 13, 2021Dr. Minnie Sarwal of NephroSant has been selected to receive the $25,000 Innovation Award
NEW YORK, NY, USA – May 13, 2021 – Lyfebulb, a patient-empowerment innovation accelerator that bridges the gap between patient communities and the healthcare industry, and CSL Behring, a...